- Summits
- Sponsorship
- Get Tickets
- Retreats
- Media Opportunities
- News
- About
Precision Neuroscience, a brain-computer interface (BCI) technology company, has raised $250 million in an oversubscribed Series D financing round co-led by Pershing Square Inc., the Ackman Oxman Institute and an undisclosed life sciences investment fund. The funding brings the company’s total capital raised to $430 million since its founding in 2021.
Additional investors include Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures and JSL Health Capital, among others.
The financing comes as Precision advances its brain-computer interface technology through clinical research, regulatory review and preparations for commercial deployment. The company reports more than 100 patient procedures across 18 major medical institutions, alongside FDA clearance for its Layer 7™ Cortical Interface and a commercial partnership with Medtronic.
Precision will use the Series D proceeds to expand its clinical program, advance Layer 7™ through the next stages of FDA review and develop the infrastructure required for commercialization.
The funding follows several milestones in the company’s development of minimally invasive brain-computer interface technology. Precision’s Layer 7™ Cortical Interface is designed to record neural activity at high resolution while remaining minimally invasive and safely removable.
According to the company, the technology has demonstrated neural recording across 4,096 electrodes and real-time decoding of intended movement. These capabilities are relevant to research into how brain signals can be interpreted and translated into actions, including potential applications in neurological rehabilitation and assistive technologies.
Precision has also established a wholly owned microelectromechanical systems (MEMS) manufacturing facility in Texas, giving it greater control over the production of its electrode arrays.
Precision reports that it has established a clinical network spanning 18 major medical institutions, which it describes as the largest clinical footprint in the brain-computer interface field. The network includes the Perelman School of Medicine at the University of Pennsylvania, University of Chicago Medicine, Mount Sinai Health System and West Virginia University’s Rockefeller Neuroscience Institute.
The company has completed more than 100 patient procedures as it continues to evaluate its technology in clinical settings. Its research collaborations have also contributed to a growing body of evidence on high-resolution neural recording.
A study published in Nature Biomedical Engineering and clinical work with Johns Hopkins University have contributed to the evaluation of Layer 7™. Separately, researchers at the University of Pennsylvania used high-resolution recordings from the interface to develop a more refined map of the human motor cortex.
Understanding the motor cortex, the brain region involved in planning and controlling voluntary movement, is important to research exploring how brain signals may support movement decoding and future neurotechnology applications.
Regulatory progress is another component of Precision’s development strategy. The company has received FDA clearance for its Layer 7™ Cortical Interface and plans to use the new funding to advance the device through further stages of FDA review.
Precision has also entered into a commercial partnership with Medtronic to integrate its technology with an established neurosurgical platform. The partnership is intended to connect Precision’s brain-computer interface technology with existing neurosurgical infrastructure.
Together, the regulatory milestone, clinical network, research collaborations and manufacturing capabilities provide a foundation for the company’s next phase of development. Further regulatory review and commercialization will be important steps as Precision works to expand the use of its technology.
The Series D round brings together investors from several categories, including venture capital firms, public-market investors, sovereign wealth funds and family offices. The participation of these groups reflects investor interest in brain-computer interfaces as an emerging area at the intersection of healthcare, neuroscience and technology.
Bill Ackman, CEO of Pershing Square and co-founder of the Ackman Oxman Institute, said neurotechnology could play a central role in the development of new treatments and rehabilitation approaches for people living with neurological injuries.
He added that Precision has the team, technology and ambition to become a leader in the BCI sector.
Michael Mager, co-founder and CEO of Precision Neuroscience, said the company’s next phase would depend on more than technological progress alone. He highlighted the importance of clinical partnerships, regulatory positioning, manufacturing capabilities and safety-focused product design.
Precision has also appointed Dr. John Donoghue, founder of BrainGate and a 2026 Queen Elizabeth Prize for Engineering laureate, as a scientific advisor.
With $430 million in total capital raised, Precision is positioning itself to advance its brain-computer interface technology beyond early clinical development and toward broader commercialization.
Its next priorities include expanding clinical activity, progressing through FDA review and building the operational infrastructure needed to bring its technology to market. The company’s progress will depend on continued clinical evaluation, regulatory developments and its ability to translate research findings into practical applications.
As investment in neurotechnology grows, Precision’s combination of clinical experience, research partnerships, manufacturing capabilities and established industry relationships will be central to its efforts to develop minimally invasive brain-computer interfaces.
At MedTech World Europe 2026, taking place on 11–13 November 2026 at the Mediterranean Conference Centre (MCC) in Valletta, Malta, the panel “The Race to Rewire the Brain: Why Investors Are Betting Big on Neurotech” will explore what is driving investment in neurotechnology and where the sector could be headed next. Join the conversation to hear perspectives on the science, business opportunities and investment priorities shaping this rapidly developing field. Book your ticket now.
